Ultrasonic Method for Testing Anti Sickling Agents

超声波法测试抗镰状化剂

• 批准号: 6527580
• 负责人: MARTIN Carl BARUCH
• 金额: $ 34.85万
• 依托单位: EMPIRICAL TECHNOLOGIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6527580
• 关键词: bioimaging /biomedical imaging; biomedical equipment development; diagnostic tests; drug screening /evaluation; hemoglobin Ss; human subject; patient oriented research; sickle cell anemia; sickling inhibitor; technology /technique development; viscosity

DESCRIPTION (provided by applicant): The results of the Phase I effort, during the course of which the blood samples of 7 HbSS patients were examined, established the feasibility of using phase-sensitive acoustic detection techniques to quantitatively monitor the polymerization of HbSS. The effects of introducing anti-sickling agents were also clearly resolved in the results. In addition, the acoustic measurements performed on 5 normal blood samples revealed the techniques sensitivity by demonstrating the reproducible resolution of the minute acoustic response to de-oxygenation of normal blood. With the basic response question settled, the primary aim of the Phase II effort will be to develop a laboratory prototype that can be used by a third party to support anti-sickling drug research efforts, general sickle cell research, as well as be potentially used as a potential diagnostic tool in clinical settings. In order to accomplish this goal, the following specific aims will be pursued under Phase II: 1. An improved experimental prototype will be designed. 2. A stable and repeatable test substrate (cell suspension) will be developed. 3. The device will be characterized extensively with regard to calibration, sensitivity, and sample variability. 4. The effects of an extensive number of anti-sickling agents will be measured. PROPOSED COMMERCIAL APPLICATION: Not Available

描述（由申请人提供）：第一阶段工作的结果 在检查过程中对 7 名 HbSS 患者的血液样本进行了检查， 确立了使用相敏声学检测的可行性 定量监测 HbSS 聚合的技术。的影响 引入抗镰状化剂在结果中也得到了明确解决。在 此外，还对 5 个正常血液样本进行了声学测量 通过展示可重复性揭示了该技术的敏感性 正常血液脱氧的微小声学反应的分辨率。 基本回答问题解决后，第二阶段的主要目标 将努力开发一个可供第三方使用的实验室原型 一方支持抗镰状细胞药物研究工作，一般镰状细胞 研究，并有可能用作潜在的诊断工具 临床环境。为实现这一目标，具体如下： 第二阶段将追求的目标： 1. 改进的实验原型将 被设计。 2. 稳定且可重复的测试底物（细胞悬液）将 得到开发。 3. 该装置的特点是广泛的 校准、灵敏度和样品变异性。 4. 的影响 将测量大量的抗镰状化剂。 拟议的商业应用： 无法使用